Gembloux, Belgium – August 20, 2026 – Full-Life Technologies (“Full-Life”, the “Company”), a fully integrated clinical-stage global radiotherapeutics company, today announced the completion of construction of its state-of-the-art manufacturing facility in Gembloux, Belgium, and the receipt of authorization to begin the commissioning and initial ramp-up phase of the facility’s accelerator

London, United Kingdom - August 14, 2026 - Full-Life Technologies ("Full-Life", the "Company"), a privately held, fully integrated clinical-stage global radiotherapeutics company, today announced its participation in ESMO Congress 2026, taking place in Madrid, Spain from October 23 to 27, 2026, and the 39th Annual Congress of the European Association of Nuclear Medicine ("EANM"), taking place in Vienna, Austria from October 17 to 21, 2026. The Company will present data from its PSMA-targeted alpha radioconjugate [225Ac]Ac-FL-020 at ESMO and from its c-MET-targeted theranostic RDC program FL-261 at EANM, where Full-Life will also host Booth 420 in Hall X-4.

Suzhou, China, and Gembloux, Belgium – May 19, 2026 – Full-Life Technologies ("Full-Life", the "Company"), a fully-integrated global radiotherapeutics company, today announced the completion of a US$150 million financing package, comprised of approximately US$110 million in Series D equity and US$40 million in debt financing. Vivo Capital led the financing, joined by Full-Life’s strategic partner SK Biopharmaceuticals Co., Ltd. and Chengwei Capital, HSG, Junson Capital, Plaisance, Sky9 Capital, Yunion, as well as other renowned shareholders.

Chengdu, China – April 8, 2026 – Full-Life Technologies ("Full-Life", the "Company"), a fully integrated clinical-stage global radiotherapeutics company, today announced its participation in the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place in San Diego, USA from April 17 to 22, 2026. The Company will have a poster presentation.

Chengdu, China – January 12, 2026 – Full-Life Technologies (“Full-Life”), a fully-integrated global radiopharmaceutical company today congratulates its partner SK Biopharmaceuticals Co., Ltd. (“SK Biopharmaceuticals”) on receiving the U.S. Food and Drug Administration (“FDA”) approval of the Phase 1 Investigational New Drug (“IND”) for its radiopharmaceutical therapeutic candidate SKL35501 and imaging agent SKL35502. The therapeutic candidate SKL35501 was in-licensed by SK Biopharmaceuticals from Full-Life in July 2024. The imaging agent SKL35502 utilizes the same NTSR1 target as SKL35501.